
THE INFLUENZA VIRUSES AND INFLUENZA

Edited by

Edwin D. Kilbourne

The Influenza Viruses and Influenza

EDITED BY

Edwin D. Kilbourne

Department of Microbiology
Mount Sinai School of Medicine
of the City University of New York
New York, New York

(内部交流)



ACADEMIC PRESS New York San Francisco London 1975

A Subsidiary of Harcourt Brace Jovanovich, Publishers

COPYRIGHT © 1975, BY ACADEMIC PRESS, INC.
ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.
111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1

Library of Congress Cataloging in Publication Data
Main entry under title:

The Influenza viruses and influenza.

Bibliography: p.

Includes index.

1. Influenza.	2. Influenza viruses.	1. Kilbourne,
Edwin D.	[DNLM: 1. Influenza.	2. Influenza Viruses.
QW160.I4 I43]		
RC150.I48	616.2'03'0194	75-13091
ISBN 0-12-407050-7		

PRINTED IN THE UNITED STATES OF AMERICA

List of Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

- William J. Bean, Jr.* (125), Waksman Institute of Microbiology, Rutgers University, New Brunswick, New Jersey
- D. Bucher* (83), Department of Microbiology, Mount Sinai School of Medicine of the City University of New York, New York, New York
- Purnell W. Choppin* (15), The Rockefeller University, New York, New York
- Richard W. Compans* (15),* The Rockefeller University, New York, New York
- R. Gordon Douglas, Jr.* (395), Departments of Medicine and Microbiology, University of Rochester School of Medicine and Dentistry, Rochester, New York
- W. R. Dowdle* (243, 315), World Health Organization, Collaborating Center for Influenza, Virology Division, Center for Disease Control, Atlanta, Georgia
- B. C. Easterday* (449), Department of Veterinary Science, University of Wisconsin, Madison, Wisconsin
- E. D. Kilbourne* (1, 483), Department of Microbiology, Mount Sinai School of Medicine of the City University of New York, New York, New York
- Hans-Dieter Klenk* (215), Institut für Virologie, Justus Liebig-Universität, Giessen, Germany
- W. Graeme Laver* (269), John Curtin School for Medical Research, Australian National University, Canberra City, Australia
- P. Palese* (83), Department of Microbiology, Mount Sinai School of Medicine of the City University of New York, New York, New York

* Present address: Department of Microbiology, University of Alabama, Birmingham, Alabama.

- Marcel W. Pons* (145), Department of Virology, The Public Health Research Institute of the City of New York, New York, New York
- G. C. Schild* (243, 315),* World Health Organization, World Influenza Center, National Institute for Medical Research, Mill Hill, London, England
- Christoph Scholtissek* (215), Institut für Virologie, Justus Liebig-Universität, Giessen, Germany
- J. L. Schulman* (373), Department of Microbiology, Mount Sinai School of Medicine of the City University of New York, New York, New York
- Irene T. Schulze* (53), Department of Microbiology, St. Louis University School of Medicine, St. Louis, Missouri
- Robert W. Simpson* (125), Waksman Institute of Microbiology, Rutgers University, New Brunswick, New Jersey
- Akira Sugiura* (171), The Institute of Public Health, Minato-ku, Tokyo, Japan
- Robert G. Webster* (269), Laboratories of Virology and Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee

* Present address: National Institute of Biological Standards and Control, Holly Hill Hamstead, London, England.

Preface

To the biased beholder and student of influenza, it is always an appropriate time to consider its chameleon complexities and review the vagaries of its protean virus. With the present decennial periodicity of pandemics of the disease, it is always just after, between, or just before major changes in the virus.

But now does seem to be a particularly propitious time for a collation of the increasingly abundant data from many laboratories on the biochemistry, structure, and function of the influenza viruses. Not because all the questions have been answered but because the problems have been isolated and better defined—and that is prelude to progress. And although the control of no infectious disease has yet depended upon a definitive understanding of the molecular biology of its causative agent, influenza may well be the first exception. Influenza vaccines, imperfect as they are, are the first to deliberately exploit genetic manipulation in their production. The epidemiology and immunity of the disease are already better understood through the recent clear definition of two discrete viral glycoproteins through which the virion interacts with the host and its environment. Studies of influenza viral structure are well advanced, and understanding of replication is progressing rapidly. On this understanding depends the development of rational approaches to chemoprophylaxis and therapy.

In a real sense, this book began in Madison, Wisconsin in September, 1971, with the first of a series of workshops on influenza sponsored by the National Institute of Allergy and Infectious Diseases. At this first informal conference (with international representation) most of the authors of this book were present, and many also attended the subsequent six conferences during the next three years. At these workshops we got to know each other well and to understand and respect each other's work. The fortunate result has been a continuing active international communication and even collaboration, as is the case with this effort to present a comprehensive view of the influenza viruses and the results of their existence.

Influenza transcends national boundaries so that this present international collaboration seems particularly appropriate.

Edwin D. Kilbourne

Contents

List of Contributors	ix
Preface	xi

1 The Influenza Viruses and Influenza—An Introduction

E. D. Kilbourne

I. Introduction—Influenza, an Unvarying Disease Caused by a Varying Virus	1
II. Taxonomy of the Influenza Viruses	3
III. A Comparison of Influenza A, B, and C Viruses—Similarities and Differences.	5
IV. Structural and Functional Relationship of Influenza Viruses to Other RNA Viruses	9
V. Antigenic Variation of Influenza Viruses Contrasted with Antigenic Variation in Other Infectious Agents	10
VI. Unanswered Questions	12
References.	13

2 The Structure of Influenza Virus

Purnell W. Chöppin and Richard W. Compans

I. Introduction	15
II. Composition of the Virus Particle	16
III. Morphology and Arrangement of Components in the Virion	30
IV. Assembly	44
V. Summary—Model of the Influenza Virion	45
References.	47

3 The Biologically Active Proteins of Influenza Virus: The Hemagglutinin

Irene T. Schulze

I. Introduction	53
II. The Hemagglutination Reaction	55
III. Structure of the Hemagglutinin	62

IV. Functions of the Hemagglutinin	73
V. Concluding Remarks	78
References	79

4 The Biologically Active Proteins of Influenza Virus: Neuraminidase

D. Bucher and P. Palese

I. Introduction	84
II. Specificity of Neuraminidase	84
III. Neuraminidase Substrates	86
IV. Chemical Properties of the Enzyme	91
V. Neuraminidase Content of the Envelope	93
VI. Characterization of the Isolated Product	100
VII. Structure of Neuraminidase	103
VIII. Neuraminidase as an Antigen	108
IX. Lectins and Neuraminidase	110
X. Inhibitors to Neuraminidase Activity	111
XI. Role of Neuraminidase	114
References	119

5 The Biologically Active Proteins of Influenza Virus: Influenza Transcriptase Activity of Cells and Virions

Robert W. Simpson and William J. Bean, Jr.

I. Introduction	125
II. RNA Polymerase Activity of Infected Cells	126
III. Virion-Associated RNA Polymerase Activity	131
IV. Concluding Remarks	141
References	141

6 Influenza Virus RNA(s)

Marcel W. Pons

I. Introduction	145
II. Methods	146
III. Physical and Chemical Characteristics of Influenza Viral RNA's	153
IV. Protein-Associated RNA (The RNP)	156
V. Intracellular Virus-Specific RNA's	159
VI. Effect of Inhibitors on RNA Synthesis	164
VII. Conclusions	167
References	167

7 Influenza Virus Genetics

Akira Sugiura

I. Introduction—Historical Review	171
II. The Influenza Viral Genome	185
III. Mutation, Variation, Adaptation, and Host-Controlled Modification	187
IV. Genetic Markers	190
V. Genetic Interactions	198

VI.	Phenotypic Mixing and Heterozygosis	206
VII.	Study of Gene Function by Characterization of <i>ts</i> Mutants	207
VIII.	Conclusions.	209
	References	209

8 Influenza Virus Replication

Christoph Scholtissek and Hans-Dieter Klenk

I.	Introduction	215
II.	Adsorption, Penetration, Uncoating.	216
III.	Transcription	219
IV.	Synthesis of Viral Proteins	224
V.	Carbohydrate Synthesis	231
VI.	Lipid Synthesis	233
VII.	Assembly	233
VIII.	Release.	236
IX.	Abnormal Forms of Multiplication	237
	References.	238

9 Laboratory Propagation of Human Influenza Viruses, Experimental Host Range, and Isolation from Clinical Materials

W. R. Dowdle and G. C. Schild

I.	Introduction	243
II.	Laboratory Propagation	244
III.	Experimental Host Range	257
IV.	Virus Isolation from Clinical Material	263
	References.	264

10 Antigenic Variation of Influenza Viruses

Robert G. Webster and W. Graeme Laver

I.	Introduction	270
II.	Historical Aspects of Influenza	272
III.	Properties of the Influenza Virus Genome	274
IV.	The Hemagglutinin and Neuraminidase Subunits as Highly Variable Antigens	275
V.	Mechanism of Antigenic Drift (Minor Antigenic Variation)	287
VI.	Mechanism of Antigenic Shifts (Major Antigenic Variation)	293
VII.	Further Evidence to Support a Recombinational Event in the Origin of New Pandemic Influenza Viruses	299
VIII.	Future Antigenic Variation in Influenza Viruses and Possibilities of Anticipating Variation and Controlling the Disease	308
	References.	310

11 Influenza Virus Characterization and Diagnostic Serology

G. C. Schild and W. R. Dowdle

I.	Introduction	316
II.	Summary of the Antigenic Components of Influenza Viruses	317
III.	Methods of Antibody Assay	319

IV.	Recommended Procedures for the Assay and Characterization of Antigens	349
V.	Recommended Procedures for Immunologic Assay	359
	References.	368
12	Immunology of Influenza	
	J. L. Schulman	
I.	Introduction	373
II.	Expressions of Immunity.	374
III.	Immune Responses Mediated by Antibody Specific for Hemagglutinin and Antibody Specific for Neuraminidase	379
IV.	Comparison of Effects of Immunity Produced by Infection and by Parenteral Immunization with Inactivated Virus	384
V.	Effect of Antigenic Drift on Immunity	386
VI.	Heterotypic Immunity	388
VII.	Original Antigenic Sin	389
VIII.	Cell-Mediated Immunity in Influenza	390
IX.	Summary	391
	References.	392
13	Influenza in Man	
	R. Gordon Douglas, Jr.	
I.	Introduction	395
II.	Naturally Occurring Influenza Virus Infection in Man	396
III.	Experimental Influenza Virus Infections in Man	419
IV.	Summary and Conclusions	441
	References.	443
14	Animal Influenza	
	B. C. Easterday	
I.	History.	449
II.	Influenza Viruses from Animals	454
III.	The Disease.	456
IV.	Epizootiology	464
V.	Control	476
	References.	477
15	Epidemiology of Influenza	
	E. D. Kilbourne	
I.	Introduction	483
II.	History.	485
III.	Influenza A, B, and C—An Epidemiological Comparison	486
IV.	Influenza A: Pandemic, Epidemic, and Endemic Disease	491
	References.	532
	Index	539

1

The Influenza Viruses and Influenza—An Introduction

E. D. Kilbourne

I. Introduction—Influenza, an Unvarying Disease Caused by a Varying Virus	1
II. Taxonomy of the Influenza Viruses	3
III. A Comparison of Influenza A, B, and C Viruses—Similarities and Differences	5
IV. Structural and Functional Relationship of Influenza Viruses to Other RNA Viruses	9
V. Antigenic Variation with Influenza Viruses Contrasted with Antigenic Variation in Other Infectious Agents	10
VI. Unanswered Questions	12
References	13

I. Introduction—Influenza, an Unvarying Disease Caused by a Varying Virus

The extraordinary attention that influenza and its causative viruses have received during the period of modern virology deserves comment in view of the very ordinary symptomatology of this generally uncomplicated infection of the human respiratory tract. The influenza virus replicates in straightforward fashion as a productive infection, without apparent recourse to latency, neoplastic induction, or other subtleties of virus–host relationship, to produce an acute inflammatory disease focused in the trachea that is attended by severe but briefly sustained fever and prostration. The disease in the typical patient has been essentially unvarying during at least the past 400 years, while, paradoxically, it has smoldered as a nuisance, or recurrently has aroused terror as the last great plague of man (Kilbourne, 1963). Paradoxically, also, the disease continues to defy control by artificial immunization despite the proved immunogenicity of specific vaccine

almost 40 years ago (Chenoweth *et al.*, 1936). In 1947, with the appearance of the H1N1 strains (Table 1.2), it was first appreciated that the magnitude of antigenic variation of influenza A virus might be so great as to circumvent previously acquired immunity to antecedent strains. Thus, the unvarying disease appears to be caused by a varying virus—indeed, by a virus unique among infectious agents in its antigenic variability. Coincident with the growing evidence of the epidemiologic complexity of influenza, its virus has proved increasingly interesting as an object of laboratory study—the first virus for which hemagglutination was demonstrated (Hirst, 1941; McClelland and Hare, 1941), the animal virus first shown to undergo “recombination” (Burnet and Lind, 1949), the virus first demonstrated to contain an enzyme as a structural protein (Hirst, 1942; Rafelson *et al.*, 1963; Kilbourne and Laver, 1966; Drzeniek *et al.*, 1966), and the virus first shown to reproduce by budding from the plasma membrane of the host cell (Murphy and Bang, 1952). Yet remarkably, research on the virus rarely has been isolated or segregated from research on the disease. The seminal early investigations of the “first generation” of scientists interested in influenza, Shope, Andrewes, Smith, Laidlaw, Stuart-Harris, Hoyle, Mulder, Burnet, Hirst, Francis, Horsfall, and Smorodintsev, have been conducted alternately at the bench and in the field, gaining lessons first from one source and then the other. This tradition has continued to the present so that many of the authors of this book could have written effectively about other aspects of influenza viruses or influenza than those assigned for their special consideration.

The last 10 years have witnessed an accelerated advance in understanding of the structure, replication, and immunology of the virus that has been in part dependent on the application of techniques widely used in molecular biology and in part upon the development of special systems and techniques for study of influenza virus. The latter include the development of plaquing and cloning systems that have facilitated genetic and antigenic studies of the virus (Simpson and Hirst, 1961; Sugiura and Kilbourne, 1965), techniques for isolation and purification of the viral polypeptides (Laver, 1963; Eckert, 1966; Compans *et al.*, 1970; Haslam *et al.*, 1970; Schulze, 1970; Skehel and Schild, 1971), the development of animal models for investigation of pathogenesis and immunity (Shope, 1931; Loosli, 1949; Schulman and Kilbourne, 1963; Nayak *et al.*, 1965; Webster *et al.*, 1971; Potter *et al.*, 1973), and the application of new serologic techniques to viral antigenic analysis and field investigations (see Schild and Dowdle, Chapter 11). The result of this activity has been a considerable increase in knowledge of the nature of the virus, a marked improvement in epidemiologic surveillance, the design of novel approaches to the fabrication of new vaccines (Chapter 15), and, as yet, no substantial impact on the incursions of the disease.

II. Taxonomy of the Influenza Viruses

The influenza viruses are relatively large enveloped viruses that contain RNA in divided or segmented form as genome. The single-stranded RNA molecules are of nonmessage polarity ["negative" in Baltimore's terminology (Baltimore, 1971)] and accordingly contain an RNA-dependent RNA transcriptase within the virion. Transcripts of the five to seven RNA segments code (probably as monocistronic messengers) for the production of five to seven virion structural proteins and possibly cell associated nonstructural protein(s) as well (see Chapters 2, 6, and 8).

As orthomyxoviruses, the influenza viruses bear certain striking similarities to the larger parainfluenza viruses of the paramyxovirus genus (Table 1.1), including the possession of negative stranded RNA and a virion transcriptase, an external envelope that contains glycoprotein spikes bearing

Table 1.1 Taxonomic Relationship of Influenza Viruses (Orthomyxoviruses) to Other RNA Animal Viruses^a

Family	Genus	"Species" ^c
Picornaviridae	<i>Enterovirus</i> <i>Rhinovirus</i> <i>Calicivirus</i>	
Togaviridae	<i>Alphavirus</i> <i>Flavivirus</i>	
— ^b	<i>Orthomyxovirus</i>	Influenza (type) A Influenza (type) B Influenza (type) C
— ^b	<i>Paramyxovirus</i>	
— ^b	<i>Coronavirus</i>	
— ^b	<i>Arenavirus</i>	
— ^b	<i>Bunyamvera</i> "supergroup" (genus provisional)	
— ^b	<i>Leukovirus</i> ("oncornavirus"; "RNA tumor viruses")	
— ^b	<i>Rhabdovirus</i>	
Reoviridae	<i>Reovirus</i> } <i>Orbivirus</i> }	"Diplornavirus" suggested

^a Based on 1971 report of International Committee on Nomenclature of Viruses (ICNV), Wildy (1971) and Fenner *et al.* (1975).

^b No family designation recognized.

^c Species designation seems appropriate on basis of absent complementation and recombination among influenza A, B, and C viruses.

Table 1.2 Taxonomy of Influenza Viruses

Family	Genus	"Species" (type)	Subtype ^a (human)	Prevalence	Antigenic variant ^b (within subtype)
None defined	<i>Orthomyxovirus</i>	Influenza A	H0N1	(?1929-1947)	Several (not listed)
			H1N1	(1946-1957)	Several (not listed)
			H2N2	(1957-1968)	Several (not listed)
			H3N2	(1968-)	Hong Kong/1/68 ^d England/42/72 Port Chalmers/1/73 Scotland/840/74
			(animal) Hsw 1N1 ^c Heq1Neq1, etc.		
		Influenza B	No true subtypes but antigenic variation may be equivalent to that observed within an influenza A subtype (e.g., H3N2)		
		Influenza C	None		Significant variation has not been defined

^a Major antigenic variant with respect to hemagglutinin and/or neuraminidase external virion antigens. Chronologic transition from one subtype to another constitutes antigenic "shift" and is usually associated with pandemic disease.

^b Minor antigenic variant within a subtype, probably resulting from series of point mutations and selection. May effectively challenge subtype-specific immunity within an interpandemic period. Antigenic "drift."

^c Probable human prototype strain of 1918-1929.

^d Strain designation is A/Hong Kong/1/68 (H3N2) [*Bull. W.H.O.* 45, 119 (1971)].

^e See Tables 14.1 and 14.2.

hemagglutinating and neuraminidase activity, and respiratory tract pathogenicity. Unlike the parainfluenza viruses, however, the influenza viruses possess a segmented genome, undergo high frequency genetic recombination or reassortment (Chapter 7), have a nuclear actinomycin D-susceptible replication phase, demonstrate no cell fusing or hemolytic properties, appear to contain hemagglutinin and neuraminidase activities in separate proteins, and have not been convincingly shown to cause persistent infections experimentally or in nature.

Influenza viruses exist as three biologically similar, but antigenically heterologous types, A, B, and C (Table 1.2). These viruses share no virus-coded antigens in common, differ in epidemiology and probably to some degree in the severity of illness that they cause. Genetic recombination, or complementation, among these types has not been verified. Therefore, the types appear to deserve identification as separate viral species (see footnote *c* to Table 1.1). *Subtypes* of influenza A virus comprise the major antigenic variants that when they first appear are associated with pandemics. Only one such subtype is present in the human population at any one time—each being superseded by the next in turn. In the case of animal influenza viruses, antigenically different subtypes can coexist (Chapters 9 and 15).

In man, significant variation in both neuraminidase and hemagglutinin antigens of a subtype is recognized every two to three years during inter-pandemic periods. Such variants probably exist as a continuum based on sequential point mutations of the original prototype strain (Chapter 10). However, rapid strain selection in nature plus inadequacies of sampling creates a picture of rather limited variation which, however, is sufficiently different among strains for their categorical definition. In each period of subtype prevalence such recognizable minor variants have appeared. Table 1.2 lists only the four minor variants of the contemporary H3N2 (Hong Kong) subtype that have thus far been associated with significant widespread epidemic disease. Such variants possess some antigenic determinants in common, but differ completely with respect to others (Laver *et al.*, 1974). The revised taxonomy of influenza virus strain designations appears in Table 1.3.

III. A Comparison of Influenza A, B, and C Viruses— Similarities and Differences

Soon after the isolation of influenza A virus from human disease, it became evident that not all cases of influenza were associated with that virus. In 1940, Francis (1940) and Magill (1940) independently isolated a virus

Table 1.3 Antigenic Characteristics of Reference Influenza A Viruses^{a, b}

Neuramin- idase subtypes	Hemagglutinin subtypes														
	H0	H1	H2	H3	Hsw1	Heq1	Heq2	Hav1	Hav2	Hav3	Hav4	Hav5	Hav6	Hav7	Hav8
N1	1	2			5								14		
N2			3	4											
Neq1						6		8	10					15	
Neq2							7								
Nav1										11	12	13			
Nav2															
Nav3								9							16
Nav4														17	
Nav5															

^a Revised from tabulated data from *Bull. W.H.O.* 45, 119 (1971).^b Previous designations:

- | | | |
|-----------------------------|-----------------------------|-------------------------------------|
| 1 = AO/PR/8/34 | 7 = A/equine-2/Miami/63 | 13 = A/tern/South Africa/61 |
| 2 = A1/FM/1/47 | 8 = A/FPV/Dutch/27 | 14 = A/turkey/Mass./65 |
| 3 = A2/Singapore/1/57 | 9 = A/turkey/England/63 | 15 = A/duck/Ukraine/1/63 |
| 4 = A2/Hong Kong/1/68 | 10 = A/chicken/Germany N/49 | 16 = A/turkey/Ontario/6118/68 |
| 5 = A/swine/Wisconsin/15/30 | 11 = A/duck/England/56 | 17 = A/Shearwater/E. Australia/1/72 |
| 6 = A/equine-1/Prague/56 | 12 = A/duck/Czech./56 | |

from human influenza that differed completely antigenically from influenza A virus. This virus, which resembled influenza A viruses in host range and biological behavior, was termed influenza B virus. Still later, in 1947, Taylor (1949) recovered a hemagglutinating virus from a subject suffering from mild upper respiratory tract infection. "Strain 1233" was originally thought to be a sporadic isolation of a virus of little public health importance, but Francis and his associates (1950) later isolated an antigenically identical virus from an epidemic of respiratory disease in children. Subsequently, the association of this virus with other episodes of mild influenza-like illness appeared to justify designation of the virus as influenza C. Difficulties in developing adequate tissue culture systems for replication of the virus and the infrequency of its demonstrable association with human disease have curtailed its study, so that much less information is available concerning its properties than is the case with influenza A and B viruses. At this writing, the presence of a viral neuraminidase has not been verified (Kendal and Kiley, 1974), nor has any other glycosidase been related to destruction of its cellular receptors (Table 1.4) that follows hemagglutination reactions. It seems probable that neuraminidase or other glycosidase activity will be found when appropriate experimental conditions have been defined.

The order of discovery of influenza A, B, and C viruses is also the rank order of these viruses with respect to their human and animal virulence, their host range in cell culture, the magnitude and frequency of antigenic variation, their optimal replication temperature, and their epidemiologic importance (see Table 1.4). Influenza A viruses differ importantly from B and C in their existence and serial transfer in lower animal species and in their association with pandemic disease—two factors that may be associated (Chapters 10 and 15). An interesting unexplained susceptibility to amantadine also differentiates influenza A from influenza B and C viruses, although some amantadine derivatives are reported to affect influenza B virus (Indulen *et al.*, 1974). An actinomycin D-sensitive step early in influenza A viral replication (indicative of a need for cellular DNA transcription) has not yet been unequivocally established for influenza B or C viruses.

Perhaps reflecting its lesser virulence and apparent predilection for the upper respiratory tract, influenza C virus differs from influenza A and B viruses in replicating (at least in the chick embryo or *in vitro* infection) most efficiently at less than mean human body temperature (37°C). Possibly this virus, and to some extent influenza B virus, are "shut off" from replication at the higher temperature of the human lung in a manner similar to selected temperature-sensitive mutants of influenza A virus (Mills and Chanock, 1971) and consequently are reduced in primary human pathogenicity.